Aiosyn and Pramana are collaborating to deliver real-time analysis of kidney structures in histology whole-slide images (WSIs).
Under the partnership, Netherlands-based Aiosyn’s NephroPath will be deployed within the AI edge compute infrastructure of US-based pathology solutions provider Pramana’s digital pathology scanners. NephroPath is a platform that uses AI-powered computational pathology algorithms to quantify kidney lesion scores,
Go deeper with GlobalData
The combined technologies allow for digital kidney pathology scans to be analysed as soon as Pramana’s scanners begin an image acquisition, with Aiosyn’s AI analysis platform running within the edge compute infrastructure of Pramana’s scanners and starting analysis before the full slide scan is complete.
According to Pramana, its digital pathology scanners with integrated edge AI compute technology are the first and only scanners to feature the technology. In edge AI computing, AI algorithms and models are deployed directly onto devices at the network ‘edge’ instead of relying on centralised cloud servers, thereby enabling real-time data processing.
The companies stated that given the technology provision, the collaboration will accelerate workflows and also strengthen data privacy and security since the need to transfer large WSI files to external systems is mitigated.
Pramana chief product officer Prasanth Perugupalli said: “Edge AI compute is opening possibilities for a future generation of digital pathology, where Pramana pioneered the concept of autonomous scanning with built-in quality assurance.
“Our partnerships with leading AI solution providers like Aiosyn offer industry-leading solutions to unique problems that were simply not possible to tackle before.”
Aiosyn and Pramana will showcase their joint solution at the United States and Canadian Academy of Pathology (USCAP) 2025 annual meeting, taking place 22-27 March in Boston, Massachusetts. Looking ahead, the companies plan to expand their partnership by integrating the detection and quantification of additional tissue structures at a later time.
Launched in March 2024, Aiosyn’s NephroPath platform can segment main tissue classes and quantify interstitial fibrosis to offer precise localisation and quantification of kidney pathologies such as glomerular disease, in which the tiny filters in the kidneys, the glomeruli, are damaged.
Beyond kidney disease, Aiosyn also specialises in AI-powered cancer pathology software. Earlier this year, the company’s Aiosyn Mitosis Breast gained a European CE mark under the European Union’s In Vitro Diagnostics Regulation (EU IVDR). The platform comprises an AI-powered solution that uses deep learning to assist pathologists in detecting mitotic figures (cell divisions) in WSIs of breast biopsies and resections.
